Lung cancer and combined pulmonary fibrosis and emphysema with anti-ARS antibody Cover

.blurhash-client-img { display: none !important; }

Lung cancer and combined pulmonary fibrosis and emphysema with anti-ARS antibody

Romanian Journal of Internal Medicine

Volume 60 (2022): Issue 3 (September 2022)

By: Riho Tanimura, Kengo Nishino, Ryosuke Iwade, Ryo Abe, Shinichiro Okauchi, Yuika Sasatani and Hiroaki Satoh

Open Access

|Sep 2022

Authors

Riho Tanimura

Division of General Medicine

Kengo Nishino

Division of Respiratory Medicine, University of Tsukuba, Mito Medical Center-Mito Kyodo General Hospital, Mito, Japan

Ryosuke Iwade

Division of General Medicine

Ryo Abe

Division of General Medicine

Shinichiro Okauchi

Division of Respiratory Medicine, University of Tsukuba, Mito Medical Center-Mito Kyodo General Hospital, Mito, Japan

Yuika Sasatani

Division of Respiratory Medicine, University of Tsukuba, Mito Medical Center-Mito Kyodo General Hospital, Mito, Japan

Hiroaki Satoh

hirosato@md.tsukuba.ac.jp

Division of Respiratory Medicine, University of Tsukuba, Mito Medical Center-Mito Kyodo General Hospital, Mito, Japan

DOI: https://doi.org/10.2478/rjim-2022-0008 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749

Journal RSS Feed

Language: English

Page range: 193 - 196

Submitted on: May 22, 2021

|

Published on: Sep 22, 2022

Published by: N.G. Lupu Internal Medicine Foundation

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

non-small cell lung cancer,

anti-aminoacyl-tRNA synthetase antibody,

combined pulmonary fibrosis and emphysema,

Related subjects:

Clinical medicine,

Internal medicine,

Internal medicine, other,

Gastroenterology,

© 2022 Riho Tanimura, Kengo Nishino, Ryosuke Iwade, Ryo Abe, Shinichiro Okauchi, Yuika Sasatani, Hiroaki Satoh, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous article Volume 60 (2022): Issue 3 (September 2022)